Clarus Therapeutics Holdings Inc

NASDAQ:CRXT   3:59:09 PM EDT
0.41
-0.02 (-3.61%)
Products, Regulatory

Clarus Therapeutics Announces Notice Of Allowance For Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) For Treatment Of Androgen-Mediated Autoimmune Inflammatory Mastitis

Published: 05/10/2022 13:30 GMT
Clarus Therapeutics Holdings Inc (CRXT) - Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering Clar-121 (testosterone + Anastrozole) for Treatment of Androgen-mediated Autoimmune Inflammatory Mastitis.
Clarus Therapeutics Holdings Inc - is Seeking Orphan Drug Designation From U.S. Food and Drug Administration in Q2 of 2022 for Clar-121.
Clarus Therapeutics Holdings Inc - Initiation of Phase 2 Clinical Trial for Clar-121 for Treatment of Pdm Anticipated in Second Half of 2022.